Understanding the Correlation Between Immune Cell Therapy and Mental Health Data: A New Approach to Preventive Medicine

Exploring the Future of Preventive Medicine

In an era where healthcare costs are surging amidst an aging populace, a new approach to medicine—preventive healthcare—has taken center stage. The collaboration between Medinet Inc. and Kokoromiru Inc. aims to delve into this promising realm by launching a clinical study in March 2026. This study will focus on individuals at high risk for cancer, assessing the efficacy of immune cell therapy combined with advanced data analytics from wearable technology.

The Shift Towards Predictive Medicine

Preventive medicine aims to forecast diseases before they manifest, allowing for proactive treatment that can either prevent or delay the onset of conditions. This revolutionary research seeks to apply immune cell therapy multiple times to subjects at elevated cancer risk, all the while exploring how their immune parameters fluctuate. Traditionally, clinical studies focus primarily on changes in immune cell counts; this endeavor distinguishes itself by also encompassing various interconnected factors like stress levels, sleep quality, nutritional status, and gut microbiome health.

Innovative Technologies at Play

Central to this multifaceted data acquisition is the wearable ECG device duranta, developed by Kokoromiru. This device has already been adopted by 22 university hospitals across Japan and enables seamless heart rate monitoring at home.

Key Features of duranta:

- Risk Visualization: Participants can easily monitor their ECG from the comfort of their homes. The ECG data will provide objective measures of stress and sleep quality, eliminating reliance on subjective assessments, which can often be misleading.

- Safety and Correlation Analysis: The study will unveil how immune cell therapy impacts bodily stress responses and heart function and how these factors influence the immune cell therapy’s effectiveness.

Building an Infrastructure for Preventive Healthcare

This innovative research is structured as a collaborative project, incorporating the expertise of various organizations. Aside from Kokoromiru, participants in this groundbreaking project include:

- Prevent Medical Co., Ltd.: Utilizing urine tests with 5-ALA for cancer risk evaluation.
- Symbiosis Solutions Co., Ltd.: Analyzing gut microbiome data using one of Japan’s largest databases and conducting nutritional evaluations informed by biodata.
- Okayama University: Jointly developed the MUSCAT-Assay, capable of detecting over 100 types of autoantibodies with exceptional sensitivity.

The overarching goal, projected to run until December 2027, is to harness the obtained information for developing future regenerative medical products and fostering new business opportunities among partner companies.

Trial Overview

- Participants: Healthy individuals with specified cancer risk factors (target sample size: 10 people).
- Duration: March 2026 – December 2027 (tentative).
- Collaborating Entities: Medinet leads the immune cell therapy aspect, while Kokoromiru specializes in visualizing heart risks, stress levels, and sleep quality, among other partners.

Expert Insights

Shoji Ikeda, Head of Regenerative Medicine Research at Medinet, expressed his enthusiasm about the research, emphasizing that the combination of immune therapy and data analysis on stress and sleep quality will significantly enhance the study's quality. He believes this effort will substantially advance preventive healthcare implementation, contributing to the establishment of a healthier society.

Daiki Hayashi, CEO of Kokoromiru, echoed these sentiments, describing their ECG analysis technology as vital in making unseen health risks visible without adding strain to users. He trusts that this collaboration will mark a significant leap towards realizing their mission of a society free from health-related regrets.

About duranta

The duranta ECG device utilized in the study is a certified medical device already employed in numerous medical facilities. Affixed to the chest, it monitors the user’s ECG during sleep, capturing potentially overlooked arrhythmias that might not be detected during routine checkups. It also measures sleep quality and stress indicators, with data processed by clinical technologists and returned in reports within days. If any abnormalities arise, participants are guided towards necessary medical actions through online consultations.